NDAINTRAVENOUS, SUBCUTANEOUSINJECTABLEPriority Review
Approved
May 2002
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
REMODULIN (treprostinil) by United Therapeutics is beds, inhibition of platelet aggregation, and inhibition of smooth muscle cell proliferation. Approved for pulmonary arterial hypertension, pulmonary hypertension. First approved in 2002.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REMODULIN (treprostinil) is a prostacycline vasodilator administered via intravenous or subcutaneous injection for pulmonary arterial hypertension and pulmonary hypertension. It works by dilating pulmonary and systemic arterial beds, inhibiting platelet aggregation, and reducing smooth muscle cell proliferation.
LOE Approaching2.9 years to LOE
REMODULIN is in late-stage commercialization with declining spending ($12M) relative to competitors, signaling a contracted team and focus on retention rather than expansion.
Mechanism of Action
beds, inhibition of platelet aggregation, and inhibition of smooth muscle cell proliferation.
Pharmacologic Class:
Prostacycline Vasodilator
Indications (2)
Worked on REMODULIN at United Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.